AIDX · 20/20 Biolabs, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q4 '24 | Q4 '23 |
|---|---|---|---|---|
| Revenue | $553.8K | - | - | - |
| Cost of Revenue | $290.5K | - | - | - |
| Gross Profit | $165.8K | - | - | - |
| R&D | $136.8K | - | - | - |
| SG&A | $1.35M | - | - | - |
| Total Operating Expenses | $938.0K | - | - | - |
| D&A | $17.8K | - | - | - |
| Operating Income | ($772.2K) | - | - | - |
| Interest Expense | $740 | - | - | - |
| Income Tax | - | - | - | - |
| Net Income | ($764.6K) | - | - | - |
| EPS - Basic | ($0.16) | - | - | - |
| EPS - Diluted | ($0.16) | - | - | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q4 '24 | Q4 '23 |
|---|---|---|---|---|
| Cash & Equivalents | $4.22M | $1.03M | $1.78M | $4.09M |
| Accounts Receivable | $201.5K | $200.0K | $135.3K | $68.8K |
| Inventory | $104.5K | $116.2K | $47.2K | - |
| Accounts Payable | $980.5K | $868.5K | $372.3K | - |
| Current Assets | $4.70M | $1.47M | $2.03M | - |
| Total Assets | $5.80M | $4.14M | $3.58M | - |
| Current Liabilities | $2.58M | $2.46M | $1.36M | - |
| Long-term Debt | - | - | - | - |
| Total Liabilities | $3.05M | $4.16M | $2.08M | - |
| Stockholders' Equity | $2.55M | ($19.2K) | $1.51M | $4.29M |
| Retained Earnings | ($35.42M) | ($33.25M) | ($29.51M) | - |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q4 '24 | Q4 '23 |
|---|---|---|---|---|
| Operating Cash Flow | ($488.3K) | - | - | - |
| Investing Cash Flow | ($5.4K) | - | - | - |
| Financing Cash Flow | $262.3K | - | - | - |
| CapEx | - | - | - | - |
| Free Cash Flow | - | - | - | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q4 '24 | Q4 '23 |
|---|---|---|---|---|
| Profitability | ||||
| Gross margin | 29.9% | - | - | - |
| Operating margin | -139.4% | - | - | - |
| EBITDA margin | -136.2% | - | - | - |
| Net margin | -138.1% | - | - | - |
| Free cash flow margin | - | - | - | - |
| FCF / Net income | - | - | - | - |
| R&D / Revenue | 24.7% | - | - | - |
| SG&A / Revenue | 244.3% | - | - | - |
| Effective tax rate | - | - | - | - |
| Return on assets | -13.2% | - | - | - |
| Return on equity | -29.9% | - | - | - |
| Return on invested capital | - | - | - | - |
| Liquidity | ||||
| Current ratio | 1.82 | 0.60 | 1.50 | - |
| Quick ratio | 1.78 | 0.55 | 1.47 | - |
| Cash ratio | 1.64 | 0.42 | 1.32 | - |
| Leverage | ||||
| Debt / Equity | - | - | - | - |
| Debt / Assets | - | - | - | - |
| Debt / EBITDA | - | - | - | - |
| Interest coverage | -1043.5x | - | - | - |
| Equity multiplier | 2.27 | -215.21 | 2.38 | - |
| Liabilities / Assets | 0.52 | 1.00 | 0.58 | - |
| Efficiency | ||||
| Asset turnover | 0.10 | - | - | - |
| Inventory turnover | 2.78 | - | - | - |
| Days sales outstanding | 133d | - | - | - |
| Days inventory outstanding | 131d | - | - | - |
| Days payable outstanding | 1232d | - | - | - |
| Cash conversion cycle | -968d | - | - | - |
| Valuation | ||||
| P / E | - | - | - | - |
| P / B | - | - | - | - |
| P / S | - | - | - | - |
| EV / EBITDA | - | - | - | - |
| Growth | ||||
| Revenue growth (YoY) | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - |
| Operating income growth (YoY) | - | - | - | - |
| Net income growth (YoY) | - | - | - | - |
| EPS growth (YoY) | - | - | - | - |
| EPS CAGR (3y) | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - |
| FCF growth (YoY) | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - |
| Book value growth (YoY) | - | - | -64.9% | - |
Peer comparison
Same SIC group: Services-Testing Laboratories
Comparing 20/20 Biolabs against the 4 most active filers in the same SIC group.